News Updates
More Articles
- Vaccine makers to produce human bird flu vaccines
- Automated stem cell production system undergoes testing
- FDA OKs Novartis' low-grade glioma drug combo for kids
- Grants support biomanufacturing partnerships in Australia
- Takeda Oncology aims for more partnership to grow its pipelines
Novartis preps for new buyback round worth $11B
Novartis is slated to initiate a share buyback round with the goal of repurchasing up to approximately $11 billion worth of shares over a three-year period. The company is currently undergoing major restructuring and has plans of spinning off Sandoz, its generics and biosimilars business. Fierce Pharma (3/13)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!